Kilitch Drugs (India) kilitch drugs held its 34th Annual General Meeting on August 27, 2026. Shareholders approved the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026.

The meeting was conducted through video conferencing and other audio-visual means, commencing at 9:00 am and concluding at 9:51 am. Mukund Mehta, Managing Director, chaired the proceedings. The company confirmed that the requisite quorum was present to transact business.

Key Resolutions

Shareholders passed several ordinary and special resolutions during the meeting. The key outcomes included:

• Approval of the audited standalone and consolidated financial statements for FY26, along with the Board of Directors’ and Auditors’ reports.
• Re-appointment of Mukund Mehta as a director retiring by rotation.
• Approval of performance-linked incentives for executive directors as a special resolution.
• Ratification of remuneration for the Cost Auditor.

Governance and Compliance

The meeting adhered to the Companies Act, 2013, and SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Proxy voting was not applicable as the AGM was held remotely. E-voting facilities were available for 15 minutes post-conclusion.

Statutory auditors C Sharat and Associates, secretarial auditor Deep Shukla & Associates, and cost auditor Arvind Kumar and Co. participated in the meeting. Voting results and the scrutinizer’s report will be disseminated to stock exchanges and published on the company website in due course.

Kilitch Drugs reported mixed financial results for the first quarter, posting revenue growth alongside a contraction in operating margins. While the company managed to expand its top line, cost pressures or lower operating leverage led to a decline in both absolute EBITDA and net profit compared to the previous year.

The pharma firm logged Q1 revenue of ₹449 million, an increase from ₹431 million recorded in the corresponding period last year. Despite this top-line expansion, the company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) slipped to ₹29 million, down from ₹33 million in the prior year quarter.

Financial Performance

The divergence between revenue growth and profit decline highlights a squeeze on operational efficiency during the period. The EBITDA margin contracted to 6.53% from 7.56% in the previous year, indicating that costs rose faster than sales. Consequently, net profit also faced downward pressure, falling to ₹29 million from ₹30 million year-on-year.

What the Numbers Show

The data reveals a clear decoupling of top-line growth from bottom-line performance. While Kilitch Drugs successfully grew its revenue base by approximately 4%, this expansion did not translate into proportional operating gains. Instead, the 12% drop in EBITDA suggests increased input costs, pricing pressures, or higher operational expenses that eroded the margin by over 100 basis points. This pattern indicates that while market share or volume may have improved, the economic value generated per rupee of sales has diminished.